Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,677,363
  • Shares Outstanding, K 66,223
  • Annual Sales, $ 44,670 K
  • Annual Income, $ -789,610 K
  • 60-Month Beta 2.10
  • Price/Sales 82.29
  • Price/Cash Flow N/A
  • Price/Book 1.84
Trade BLUE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -3.09
  • Number of Estimates 12
  • High Estimate -0.98
  • Low Estimate -3.81
  • Prior Year -3.73
  • Growth Rate Est. (year over year) +17.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.45 +7.93%
on 10/02/20
59.06 -5.98%
on 10/12/20
-0.42 (-0.75%)
since 09/23/20
3-Month
51.45 +7.93%
on 10/02/20
68.39 -18.80%
on 08/06/20
-9.73 (-14.91%)
since 07/23/20
52-Week
38.95 +42.57%
on 03/17/20
99.36 -44.11%
on 01/17/20
-30.62 (-35.54%)
since 10/23/19

Most Recent Stories

More News
Bluebird Bio Inc Rises 1.13% on Heavy Volume: Watch For Potential Pullback

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $57.74 to a high of $58.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high...

BLUE : 55.53 (+0.04%)
GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

NVS : 84.43 (+0.02%)
GLYC : 3.23 (+0.31%)
BLUE : 55.53 (+0.04%)
GBT : 56.36 (-0.25%)
bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA

bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.

EBS : 96.11 (-1.58%)
HZNP : 77.44 (+1.81%)
LGND : 85.02 (+0.33%)
BLUE : 55.53 (+0.04%)
Researchers Look for New Ways to Boost Diagnostic Capabilities

, /PRNewswire/ -- The global cancer diagnostics market is of the more innovative segments of the global diagnostics industry today. Cancer is one of the leading causes of death across the world, and its...

ANPC : 3.59 (+2.57%)
BLUE : 55.53 (+0.04%)
GSK : 35.29 (+0.57%)
EXEL : 22.29 (+2.11%)
EXAS : 109.70 (+2.44%)
bluebird bio Announces European Medicines Agency's Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D(TM)) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the European Medicines Agency (EMA) accepted the company's marketing authorization application (MAA) for its investigational elivaldogene autotemcel...

BLUE : 55.53 (+0.04%)
bluebird bio to Present at Jefferies Cell Therapy Virtual Summit

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET.

BLUE : 55.53 (+0.04%)
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA

The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.

BMY : 60.13 (-1.04%)
EBS : 96.11 (-1.58%)
TECH : 268.46 (-0.45%)
BLUE : 55.53 (+0.04%)
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

BMY : 60.13 (-1.04%)
SGEN : 196.92 (-1.86%)
BLUE : 55.53 (+0.04%)
ARWR : 58.88 (+0.55%)
BPMC : 104.67 (+1.80%)
VCNX : 1.8800 (-0.53%)
bluebird bio's LentiGlobin(TM) for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency

bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin(TM) for SCD gene therapy (bb1111), was granted eligibility to the Priority...

BLUE : 55.53 (+0.04%)
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

-- Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma

BMY : 60.13 (-1.04%)
BLUE : 55.53 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

2nd Resistance Point 56.65
1st Resistance Point 56.09
Last Price 55.53
1st Support Level 54.88
2nd Support Level 54.23

See More

52-Week High 99.36
Fibonacci 61.8% 76.28
Fibonacci 50% 69.15
Fibonacci 38.2% 62.03
Last Price 55.53
52-Week Low 38.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar